Beneficial Effects of Isoproterenol and Quinidine in the Treatment of Ventricular Fibrillation in Brugada Syndrome
The use of an implantable cardiac defibrillator has been advocated as the only effective treatment for the management of ventricular fibrillation (VF) in patients with Brugada Syndrome (BrS). However, this device is only useful for terminating VF. Intermittent and/or recalcitrant VF for which lifesa...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Cardiology |
| Online Access: | http://dx.doi.org/10.1155/2015/753537 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849305622124691456 |
|---|---|
| author | Melissa Dakkak Khyati Baxi Ambar Patel |
| author_facet | Melissa Dakkak Khyati Baxi Ambar Patel |
| author_sort | Melissa Dakkak |
| collection | DOAJ |
| description | The use of an implantable cardiac defibrillator has been advocated as the only effective treatment for the management of ventricular fibrillation (VF) in patients with Brugada Syndrome (BrS). However, this device is only useful for terminating VF. Intermittent and/or recalcitrant VF for which lifesaving cardioversion occurs is a problematic situation in this patient population. The immediate use of appropriate antiarrhythmics in the acute setting has proven to be lifesaving. Quinidine has been well established as an effective antiarrhythmic in BrS, while isoproterenol (ISP) has had some recognition as well. The addition of drug therapy to prevent the induction of these arrhythmias has been shown to reduce the morbidity and mortality associated with BrS. It was proven to be especially effective in the presence of early repolarization, evidenced by the reduction or normalization of the early repolarization pattern on ECG. Thus, for the prophylactic management and long term suppression of VF in BrS, further prospective studies should be performed to determine the effectiveness of quinidine and ISP in this patient population. |
| format | Article |
| id | doaj-art-0679de52ddef496293d3b38040971e20 |
| institution | Kabale University |
| issn | 2090-6404 2090-6412 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Cardiology |
| spelling | doaj-art-0679de52ddef496293d3b38040971e202025-08-20T03:55:23ZengWileyCase Reports in Cardiology2090-64042090-64122015-01-01201510.1155/2015/753537753537Beneficial Effects of Isoproterenol and Quinidine in the Treatment of Ventricular Fibrillation in Brugada SyndromeMelissa Dakkak0Khyati Baxi1Ambar Patel2Departments of Cardiovascular Diseases and Internal Medicine, University of Florida Health, Jacksonville, FL 32209, USADepartments of Cardiovascular Diseases and Internal Medicine, University of Florida Health, Jacksonville, FL 32209, USADepartments of Cardiovascular Diseases and Internal Medicine, University of Florida Health, Jacksonville, FL 32209, USAThe use of an implantable cardiac defibrillator has been advocated as the only effective treatment for the management of ventricular fibrillation (VF) in patients with Brugada Syndrome (BrS). However, this device is only useful for terminating VF. Intermittent and/or recalcitrant VF for which lifesaving cardioversion occurs is a problematic situation in this patient population. The immediate use of appropriate antiarrhythmics in the acute setting has proven to be lifesaving. Quinidine has been well established as an effective antiarrhythmic in BrS, while isoproterenol (ISP) has had some recognition as well. The addition of drug therapy to prevent the induction of these arrhythmias has been shown to reduce the morbidity and mortality associated with BrS. It was proven to be especially effective in the presence of early repolarization, evidenced by the reduction or normalization of the early repolarization pattern on ECG. Thus, for the prophylactic management and long term suppression of VF in BrS, further prospective studies should be performed to determine the effectiveness of quinidine and ISP in this patient population.http://dx.doi.org/10.1155/2015/753537 |
| spellingShingle | Melissa Dakkak Khyati Baxi Ambar Patel Beneficial Effects of Isoproterenol and Quinidine in the Treatment of Ventricular Fibrillation in Brugada Syndrome Case Reports in Cardiology |
| title | Beneficial Effects of Isoproterenol and Quinidine in the Treatment of Ventricular Fibrillation in Brugada Syndrome |
| title_full | Beneficial Effects of Isoproterenol and Quinidine in the Treatment of Ventricular Fibrillation in Brugada Syndrome |
| title_fullStr | Beneficial Effects of Isoproterenol and Quinidine in the Treatment of Ventricular Fibrillation in Brugada Syndrome |
| title_full_unstemmed | Beneficial Effects of Isoproterenol and Quinidine in the Treatment of Ventricular Fibrillation in Brugada Syndrome |
| title_short | Beneficial Effects of Isoproterenol and Quinidine in the Treatment of Ventricular Fibrillation in Brugada Syndrome |
| title_sort | beneficial effects of isoproterenol and quinidine in the treatment of ventricular fibrillation in brugada syndrome |
| url | http://dx.doi.org/10.1155/2015/753537 |
| work_keys_str_mv | AT melissadakkak beneficialeffectsofisoproterenolandquinidineinthetreatmentofventricularfibrillationinbrugadasyndrome AT khyatibaxi beneficialeffectsofisoproterenolandquinidineinthetreatmentofventricularfibrillationinbrugadasyndrome AT ambarpatel beneficialeffectsofisoproterenolandquinidineinthetreatmentofventricularfibrillationinbrugadasyndrome |